Bristol's Eliquis approved to prevent clots after hip, knee surgery
March 14 (Reuters) - U.S. regulators have approved an additional use of Bristol-Myers Squibb Co's blood clot preventer Eliquis, to prevent blood clots in the legs and lungs of patients who have undergone surgery to receive artificial hips or knees.
The drug is already sold in partnership with Pfizer Inc to prevent blood clots that can cause strokes in patients with atrial fibrillation, an irregular heartbeat that is most common in the elderly.
- Police seek motive in fatal Washington state school shooting
- Wall St. finally turning on Amazon as Bezos magic fades
- Two deputies killed, two others hurt in California shooting spree
- Easter Island's ancient inhabitants weren't so lonely after all
- Two killed, four wounded in Washington state school shooting